129 related articles for article (PubMed ID: 15558327)
1. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Milton DT; Kris MG; Gomez JE; Feinstein MB
Support Care Cancer; 2005 Jan; 13(1):70-2. PubMed ID: 15558327
[TBL] [Abstract][Full Text] [Related]
2. Severe bronchorrhea in a patient with bronchioloalveolar carcinoma.
Popat N; Raghavan N; McIvor RA
Chest; 2012 Feb; 141(2):513-514. PubMed ID: 22315118
[TBL] [Abstract][Full Text] [Related]
3. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
Yano S; Kanematsu T; Miki T; Aono Y; Azuma M; Yamamoto A; Uehara H; Sone S
Cancer Sci; 2003 May; 94(5):453-8. PubMed ID: 12824893
[TBL] [Abstract][Full Text] [Related]
4. [Gefitinib for advanced bronchioloalveolar carcinoma].
Zhang XT; Wang SL; Li LY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Jun; 26(3):340-3. PubMed ID: 15266843
[TBL] [Abstract][Full Text] [Related]
5. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
Kitazaki T; Fukuda M; Soda H; Kohno S
Lung Cancer; 2005 Jul; 49(1):125-8. PubMed ID: 15949598
[TBL] [Abstract][Full Text] [Related]
6. [EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Svoboda M; Fabian P; Slabý O; Stanková M; Lakomý R; Nemecek R; Vyzula R
Klin Onkol; 2010; 23(4):224-30. PubMed ID: 20806820
[TBL] [Abstract][Full Text] [Related]
7. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Cadranel J; Quoix E; Baudrin L; Mourlanette P; Moro-Sibilot D; Morere JF; Souquet PJ; Soria JC; Morin F; Milleron B;
J Thorac Oncol; 2009 Sep; 4(9):1126-35. PubMed ID: 19574932
[TBL] [Abstract][Full Text] [Related]
8. Bronchioloalveolar carcinoma: not as easy as "BAC".
West HL; Garfield DH
J Thorac Oncol; 2009 Sep; 4(9):1047-8. PubMed ID: 19704334
[No Abstract] [Full Text] [Related]
9. Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Sanz Rubiales A; de la Cruz V; Berezo JÁ; Torres MÁ
J Pain Symptom Manage; 2014 Jun; 47(6):e7-9. PubMed ID: 24747679
[No Abstract] [Full Text] [Related]
10. Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.
Chang GC; Yang TY; Wang NS; Huang CM; Chiang CD
J Formos Med Assoc; 2003 Jun; 102(6):407-11. PubMed ID: 12923594
[TBL] [Abstract][Full Text] [Related]
11. Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Taja-Chayeb L; Candelaria M; Brom R; Trejo-Becerril C; Meza F; Duenas-Gonzalez A
Lung Cancer; 2005 Nov; 50(2):259-63. PubMed ID: 16009451
[TBL] [Abstract][Full Text] [Related]
12. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
[TBL] [Abstract][Full Text] [Related]
13. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
14. Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
Pastorino U; Calabrò E; Tamborini E; Marchianò A; Orsenigo M; Fabbri A; Sozzi G; Novello S; De Marinis F
J Thorac Oncol; 2009 Feb; 4(2):266-7. PubMed ID: 19179908
[TBL] [Abstract][Full Text] [Related]
15. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
Gandara DR; West H; Chansky K; Davies AM; Lau DH; Crowley J; Gumerlock PH; Hirsch FR; Franklin WA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4205s-4209s. PubMed ID: 15217959
[TBL] [Abstract][Full Text] [Related]
16. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
Dziadziuszko R; Siemiatkowska A; Limon J; Rzyman W; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
J Thorac Oncol; 2007 Jan; 2(1):91-2. PubMed ID: 17410018
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
West HL; Franklin WA; McCoy J; Gumerlock PH; Vance R; Lau DH; Chansky K; Crowley JJ; Gandara DR
J Clin Oncol; 2006 Apr; 24(12):1807-13. PubMed ID: 16622257
[TBL] [Abstract][Full Text] [Related]
18. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Wislez M; Antoine M; Baudrin L; Poulot V; Neuville A; Pradere M; Longchampt E; Isaac-Sibille S; Lebitasy MP; Cadranel J
Lung Cancer; 2010 May; 68(2):185-91. PubMed ID: 19581016
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma.
Homma S; Kawabata M; Kishi K; Tsuboi E; Narui K; Nakatani T; Nakata K
Chest; 1999 May; 115(5):1465-8. PubMed ID: 10334175
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma].
Bayle S; Descourt R; Gouva S; Daniel C; Robinet G
Rev Mal Respir; 2004 Feb; 21(1):153-7. PubMed ID: 15260051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
